Live Breaking News & Updates on Immaterial Misstatements

Stay updated with breaking news from Immaterial misstatements. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Exchange Commission , Therapeutics Provides Business Update , Reports Third Quarter , Janssen Biotech , Steve Hurly , Immaterial Misstatements , Consolidated Interim Statements , Comprehensive Profit , Consolidated Statements , Middle East ,

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by SeagenPortfolio reprioritization and extension of cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 22, 2023 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ....

United States , Janssen Biotech Inc , Drug Administration , Exchange Commission , Janssen Biotech , Steve Hurly , Janssen Agreement , Immaterial Misstatements , Consolidated Interim Statements , Consolidated Statements , Financial Position , Lava Therapeuticsnv , The Company , Lava Therapeutics ,

2023-08-22 | NDAQ:LVTX | Press Release | LAVA Therapeutics NV

(2023-08-22 | NDAQ:LVTX) LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results ....

United States , Company Closecurlyquote , Drug Administration , Exchange Commission , Janssen Biotech Inc , Janssen Biotech , Steve Hurly , Janssen Agreement , Immaterial Misstatements , Consolidated Interim Statements , Consolidated Statements , Financial Position , Cautionary Note , Factors Closecurlydoublequote , Lava Therapeutics Nv , Healthcare 37 , Biotechnology 121 , Usa 8 , Biotechnology 70569 ,

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to provide cash runway into 2026 UTRECHT, The. | June 8, 2023 ....

United States , Robin Hume , Jazz Pharmaceuticals , Head Of Regulatory Affairs , Janssen Biotech Inc , Regulatory Affairs At Gentium , Janssen Biotech , Stephen Hurly , Regulatory Affairs , Immaterial Misstatements , Consolidated Statements , Financial Position ,

LAVA Therapeutics N : Consolidated Financial Statements - Form 6-K

Table of Contents

Exhibit 99.1

LAVA THERAPEUTICS N.V.

INDEX TO UNAUDITED. | June 8, 2023 ....

United States , Stichting Vumc , Dutch Research , International Financial Reporting Standards , International Accounting Standards Board , Development Act , Seagen Inc , International Accounting Standard , Exchange Commission , Seagen Agreement The Company , Janssen Biotech Inc , Development Expenses , Consolidated Interim Statements , Months Ended March , Nasdaq Global Select , Audit Committee , Significant Accounting , International Accounting Standards , Accounting Policies , Immaterial Misstatements , Significant Accounting Judgments , Seagen Agreement , Janssen Agreement , Janssen Biotech , Option Plan , Term Incentive Option Plan ,